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Abstract: Pancreatic adenocarcinoma up-regulated factor (PAUF) expression is elevated in both ovarian tumors 
and pancreatic adenocarcinoma. However, PAUF expression in ovarian tumors according to histologic subtype and 
grade has not been investigated. In this study, we examined various clinicopathologic features of 24 patients with 
mucinous cystadenoma (MCA), 36 with mucinous borderline tumors (MBTs), and 46 with mucinous adenocarcino-
mas (MACs) according to PAUF expression status assessed using immunohistochemistry. We found that MACs more 
frequently stained positive for PAUF than did MCAs and MBTs (P < 0.0001). Although there was no significant differ-
ences with respect to other clinicopathologic characteristics of MACs according to PAUF expression status, patients 
with PAUF-weakly positive and PAUF-strongly positive MACs tended to have a shorter overall survival (OS) than those 
with PAUF-negative MAC, determined using a Kaplan–Meier analysis (P = 0.1885). After adjusting for various clini-
copathologic parameters, PAUF positivity of MACs was a significant predictive factor for disease-free survival (DFS) 
(negative vs. weakly positive: P = 0.045, hazard ratio [HR] = 57.406, 95% confidence interval [CI]: 1.090-3022.596; 
and negative vs. strongly positive: P = 0.034, HR = 97.890, 95% CI: 1.412-6785.925). In conclusion, PAUF was more 
frequently expressed in MAC than in its benign and borderline counterparts, and was associated with a poor OS and 
DFS in MAC patients. Therefore, we suggest that PAUF may be a practical biomarker for histopathological categoriza-
tion and a prognostic marker for patients with an ovarian mucinous tumor. 
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Introduction 
Ovarian mucinous neoplasm is a common ovar-
ian epithelial tumor. It is categorized as benign 
mucinous cystadenoma (MCA), mucinous bor-
derline tumor (MBT) of intermediate grade, and 
malignant mucinous adenocarcinoma (MAC) 
based on its biological behavior [1, 2]. Of these, 
MCA is the most common ovarian mucinous 
neoplasm, accounting for 14% of all ovarian 
tumors and approximately 80% of all primary 
ovarian mucinous tumors [3]. MBTs, which are 
associated with an excellent prognosis and 
have a survival rate of > 90%, are the most 
common type of borderline ovarian tumor in 
Asia and the second most common in North 
America and Europe [4-8]. In contrast, ovarian 
MAC accounts for 3-4% of all primary ovarian 
carcinomas and is known to have an aggressive 
behavior, often recurring early and showing 
resistance to chemotherapy and radiotherapy 
[9, 10]. It is therefore important to distinguish 
between these tumor subtypes; however, there 
are no suitable biomarkers to that can help to 
differentiate between intermediate and malig-
nant mucinous tumors.
Pancreatic adenocarcinoma up-regulated fac-
tor (PAUF) is a novel, tumor-specific protein [11]. 
It is known to play an important role in cancer 
progression and metastasis in pancreatic duc-
tal adenocarcinoma [11, 12]. In addition, Kim et 
al. demonstrated that PAUF was also highly 
expressed in colon and ovarian tumors using 
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Number of cases 24 36 46
Age at diagnosis (years, mean ± SD) 49.25 ± 3.632 44.36 ± 2.502 43.26 ± 2.122 0.2951
Stage (%) < 0.0001
    Localized - 34 (94.44) 22 (47.83)
    Regional - 2 (5.56) 14 (30.43)
    Distant - 0 10 (21.74)
Histologic subtype (%)
    Intestinal - 30 (83.33) -
    Endocervical - 6 (16.67) -
Invasion pattern (%)
    Expansile - - 37 (80.43)
    Infiltrative - - 9 (19.57)
PAUF expression (%) < 0.0001
    Negative 16 (66.67) 27 (75.00) 10 (21.74)
    Weakly positive 7 (29.17) 5 (13.89) 19 (41.30)
    Strongly positive 1 (4.17) 4 (11.11) 17 (36.96)
SD, standard deviation.
Northern blot analysis [11]. However, the 
expression profiles of PAUF in ovarian neo-
plasms according to histologic subtype or 
malignant potential are not known. In this study, 
we evaluated PAUF expression status accord-
ing to the histologic grade of ovarian mucinous 
neoplasms and investigated its potential as a 
prognostic biomarker.
Materials and methods
Case selection and tumor samples
The study cohort consisted of 24 patients with 
MCA, 36 patients with MBT, and 46 patients 
with MAC who had undergone surgery and were 
diagnosed at Yonsei University Medical Center 
between 2001 and 2012. This retrospective 
study was approved by the institutional review 
board of Yonsei University Medical Center (IRB 
no. 4-2014-0034). The following clinical param-
eters were recorded: age at diagnosis, tumor 
stage, follow-up duration, and survival. We 
grouped cases of mucinous neoplasms using 
the International Federation of Gynecology and 
Obstetrics (FIGO) staging criteria at diagnosis. 
These groups were a localized stage including 
FIGO stages IA and IB, a regional stage includ-
ing FIGO stages IC and II, and a distant stage 
including FIGO stages III and IV.
Tissue samples were fixed in 10% buffered for-
malin and embedded in paraffin. Archival tis-
sues stained with hematoxylin and eosin (H&E) 
were reviewed by two obstetrics and gynecolo-
gy pathologists (SK Kim and NH Cho). A repre-
sentative area was selected on an H&E-stained 
slide and the corresponding area was marked 
on the formalin-fixed paraffin-embedded (FFPE) 
tissue block to make a tissue microarray (TMA), 
with 5 mm tissue cores. The pathologic param-
eters included the histologic subtype of MBT, 
invasion patterns of MAC, PAUF expression, 
estrogen receptor (ER) expression, and Ki-67 
labeling index (LI).
Immunohistochemistry
We used an anti-recombinant human PAUF 
(antirhPAUF) polyclonal antibody (pAb) which 
was kindly provided by Dr. Sun A Kim [11]. 
Immunohistochemistry was performed using 
5-μm-thick sections cut from a TMA block using 
a microtome. These were transferred onto 
adhesive slides and dried at 70°C for 30 min. 
Immunohistochemistry with anti-rhPAUF pAb 
(diluted 1:200), ER antibody (Thermo Scientific, 
diluted 1:100), and Ki-67 (Abcam, diluted 
1:1000) was performed using a Dako Envision 
Kit following the manufacturers’ instructions. 
Interpretation of immunohistochemical stain-
ing
We divided ovarian mucinous tumors into three 
groups based on the immunostaining intensity 
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Figure 1. PAUF expression in ovarian mucinous 
neoplasms. A. Immunohistochemical staining for 
PAUF protein in mucinous neoplasms of the ovary. 
PAUF-negative tumor cells (bottom, two left pan-
els), PAUF-weakly positive tumor cells (bottom, 
middle of the panels), and PAUF-strongly positive 
tumor cells (bottom, two right panels).  Magnifica-
tion, ×200. B. The proportion of tumors with strong, 
weak, or negative PAUF expression according to 
histologic grade. MCA, mucinous cystadenoma; 
MBT, mucinous borderline tumor; MAC, mucinous 
adenocarcinoma.
of PAUF: 0 (negative), 1 (weakly positive) and 2 
(strongly positive). The proportion of PAUF-
stained cells was scored as 0 (negative), 1 (< 
10%) and 2 (> 10%). The final score for each 
tumor was calculated by multiplying the immu-
nostaining intensity by the proportion of stained 
cells, and was then categorized as follows: 0-1, 
negative; 2, weakly positive; and 4, strongly 
positive. 
A cut-off value of > 1% of nuclei that were 
strongly stained was used to define ER expres-
sion [13]. To establish the cutoff Ki-67 LI, we 
analyzed the Ki-67 LI of ovarian mucinous 
tumors using receiver operator characteristic 
(ROC) curves according to PAUF positivity and 
determined that 1.167% (sensitivity: 70.4%, 1 
- specificity: 84.8%) was the optimal cutoff 
value.
Statistics
Statistical analyses were performed using 
GraphPad Prism 5 software, version 5.01 
(GraphPad Software, Inc., La Jolla, CA, USA) 
and SPSS for Windows, version 12.0 (SPSS 
Inc., Chicago, IL, USA). For the analysis of age at 
diagnosis, a significant difference between 
means was determined by analysis of varianc-
es (ANOVA). Follow-up durations of patients 
with MBT and MAC were compared using a 
t-test. FIGO stage, histologic subtypes, invasion 
patterns, and the expressions of PAUF, ER, and 
Ki-67 LI were compared using the chi-square 
and Fisher’s exact test. Kaplan-Meier survival 
curves and log-rank statistics were employed 
to evaluate overall survival (OS) and disease-
free survival (DFS). Univariate and multivariate 
regression analyses were performed using the 
Cox proportional hazards model. All reported 
P-values are two-sided, and P-values <0.05 
were considered statistically significant.
Results
Clinicopathologic features of ovarian mucinous 
neoplasms
Ovarian mucinous neoplasms are categorized 
as benign, intermediate, or malignant based on 
their pathologic features, and are referred to as 
MCA, MBT, and MAC, respectively [2]. We 
selected 24 cases of MCA, 36 cases of MBT, 
and 46 cases of MAC and compared the clinico-
pathologic features of these ovarian mucinous 
neoplasms (Table 1). 
There was no significant difference in the medi-
an age at diagnosis of patients with MCA (49.25 
± 3.632 years), MBT (44.36 ± 2.502 years), 
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Table 2. Clinicopathologic features of 36 MBTs according to PAUF expression status 
PAUF expression
P-value
Negative Weakly positive Strongly positive
Number of cases 27 (75.00) 5 (13.89) 4 (11.11)
Age at diagnosis (years, mean ± SD) 45.96 ± 2.864 46.40 ± 7.954 31.00 ± 2.273 0.1697
Stage
    Localized 25 5 4
    Regional 2 0 0
    Distant 0 0 0
Histologic subtype 0.1466
    Intestinal 24 4 2
    Endocervical 3 1 2
ER status 0.1466
    Negative 24 4 2
    Positive 3 1 2
Ki-67 LI *0.0863
    < 1.167% 4 1 3
    ≥ 1.167% 23 4 1
SD, standard deviation. *We calculated P-value using Fisher’s exact test after grouping PAUF weakly positive and strongly posi-
tive MBTs together as PAUF-positive MBTs and compared them with PAUF-negative MBTs, because the chi-square calculation is 
not valid when all expected values are < 1.
Table 3. Clinicopathologic features of 46 MACs according to PAUF expression status 
 PAUF expression
P-value
Negative Weakly positive Strongly positive
Number of cases 10 19 17
Age at diagnosis (years, mean ± SD) 40.40 ± 3.933 39.58 ± 2.838 49.06 ± 3.957 0.1095
Follow-up (months, mean ± SD) 69.10 ± 12.96 53.74 ± 8.538 37.53 ± 5.829 0.0696
Overall survival (%) 10/10 (100.000) 14/19 (73.684) 13/17 (76.471) 0.1885
Disease-free survival (%) 9/10 (87.500) 13/19 (60.014) 12/17 (63.995) 0.3732
Stage 0.2205
    Localized 3 10 9
    Regional 3 4 7
    Distant 4 5 1
Invasion pattern (%) 0.5464
    Expansile 8 14 15
    Infiltrative 2 5 2
SD, standard deviation.
and MAC (43.26 ± 2.122, P = 0.2951). We 
grouped cases of MBTs and MACs based on 
FIGO stage and categorized them as being 
localized, regional, or distant. Most MBT cases 
were at a localized stage, whereas most MCA 
cases were at a regional or distant stage (P < 
0.0001). 
For a more detailed analysis, we subdivided 
MBTs into two groups according to the histo-
logic features of their epithelial component: 
intestinal type or endocervical type [2]. 
According to the most recent World Health 
Organization classification of female reproduc-
tive organs, endocervical-type MBTs are con-
sidered a subset of seromucinous tumors, 
referred to as seromucinous borderline tumors 
[14]. However, to date, seromucinous border-
line tumors have been reported as endocervi-
cal-type MBTs and compared with other intesti-
nal-type MBTs. Therefore, we included 
endocervical-type MBTs (seromucinous border-
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Figure 2. Survival analysis of patients with ovarian mucinous adenocarcinoma according to PAUF expression. A. 
Overall survival of MAC patients according to PAUF expression status. B. Disease-free survival of MAC patients ac-
cording to PAUF expression status.
line tumors) in this study to clarify the clinico-
pathological features of intestinal-type MBTs. 
Thirty of the 36 MBTs (83.33%) had an epithe-
lial component resembling intestinal epitheli-
um, and the other six cases (16.67%) exhibited 
mucinous epithelial cells resembling endocervi-
cal epithelium. This finding is similar to those of 
previous reports, in which the intestinal type 
accounted for 85-90% of MBTs and the endo-
cervical type for 10-15% [7, 15-17].
MACs were subdivided into expansile and infil-
trative types according to their invasion pat-
terns, rather than a grading system, because it 
is well established that the current grading sys-
tem for mucinous carcinoma can predict nei-
ther tumor behavior nor treatment response 
[15, 16, 18]. However, infiltrative stromal inva-
sion has proved to be more biologically aggres-
sive than expansile invasion [2]. We found infil-
trative invasion growth in nine out of 46 MACs 
(19.57%) and an expansile invasion pattern in 
37 out of 46 MACs (80.43%).
PAUF expression status according to subtypes 
of ovarian mucinous tumors
We performed immunohistochemical staining 
with antirhPAUF pAb on FFPE tissue of ovarian 
mucinous neoplasms, and interpreted PAUF 
reactivity as negative, weakly positive, or 
strongly positive as described above (Figure 
1A). Interestingly, MACs most frequently dem-
onstrated weak PAUF positivity (19 of 46 cases, 
41.30%) and strong PAUF positivity (17 of 46 
cases, 36.96%), in contrast to MCAs (weakly 
positive: 29.17%, strongly positive: 4.17%) and 
MBTs (weakly positive: 13.89%, strongly posi-
tive: 8.33%; Table 1 and Figure 1B, P < 0.0001). 
Thus, strongly positive PAUF staining was more 
common in ovarian mucinous tumors with more 
aggressive behavior.
Clincopathologic features of MBTs according 
to PAUF expression status
We next compared the clinicopathologic fea-
tures of MBTs according to their PAUF expres-
sion status (Table 2). Although only four of 36 
MBTs were strongly positive for PAUF, these 
cases tended to occur 10 years earlier (31.00 ± 
2.273 years) than their PAUF negative (45.96 ± 
2.864 years) or weakly positive PAUF (46.40 ± 
7.954 years) equivalents, although these differ-
ences were not statistically different (P = 
0.1697). Differences in tumor stage according 
to PAUF expression status could not be statisti-
cally analyzed because most MBTs were at a 
localized stage, except for two cases at a 
regional stage.
Chi-square calculations are usually only valid 
when all expected values are > 1, and this con-
dition was not met when we assessed the 
pathologic features of MBTs according to PAUF 
expression status. Therefore, we combined 
MBTs that were either weakly or strongly posi-
tive for PAUF as a single PAUF-positive group (n 
= 9) and compared their pathologic parameters 
with those of the PAUF-negative group (n = 27) 
using Fisher’s exact test. This revealed no sta-
tistically significant differences with respect to 
histologic subtype or ER status. However, all of 
the endocervical MBTs were ER positive, as 
they are known [19]. There were also no signifi-
cant differences between PAUF-positive and 
negative MBTs with respect to the Ki-67 LI, a 
marker of proliferative activity.
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Table 4. Univariate analysis for overall survival and disease-free survival
Parameter 
Overall survival Disease-free survival 
P-value Hazard ratio 95% CI P-value Hazard ratio 95% CI 
Age 0.002 1.097 1.034-1.164 0.001 1.090 1.038-1.146 
Stage 0.014 0.009 
    Localized vs. regional 0.808 0.741 0.067-8.256 0.385 2.213 0.369-13.263 
    Localized vs. distant 0.016 7.099 1.431-35.206 0.006 9.175 1.899-44.334 
Invasion 
    Expansile vs. infiltrative 0.091 3.117 0.835-11.636 0.088 2.724 0.863-8.599 
PAUF 0.960 0.425 
    Negative vs. weakly positive 0.948 0.230 3.655 0.440-30.369 
    Negative vs. strongly positive 0.947 0.197 4.134 0.480-35.618 
Table 5. Multivariate analysis for overall survival and disease-free survival
Parameter 
Overall survival Disease-free survival 
P-value Hazard ratio 95% CI P-value Hazard ratio 95% CI 
Age 0.042 1.116 1.004-1.240 0.044 1.083 1.002-1.170 
Stage 0.024 0.080 
    Localized vs. regional 0.378 0.313 0.024-4.131 0.882 1.159 0.164-8.184 
    Localized vs. distant 0.021 23.365 1.605-340.079 0.037 9.941 1.142-86.496 
Invasion 
    Expansile vs. infiltrative 0.640 0.626 0.088-4.450 0.823 1.218 0.216-6.884 
PAUF 0.809 0.099 
    Negative vs. weakly positive 0.941 0.045 57.406 1.090-3022.596
    Negative vs. strongly positive 0.937 0.034 97.890 1.412-6785.925
MAC PAUF expression is associated with 
shorter OS and DFS
As described above, MACs more frequently 
stain positive for PAUF than other ovarian muci-
nous tumors. We therefore compared the clini-
copathologic features of MACs according to 
PAUF expression (Table 3). There was no signifi-
cant difference in age at diagnosis, tumor 
stage, and invasion pattern in MACs with 
respect to PAUF expression. 
When we compared the OS and DFS of MAC 
patients according to PAUF expression status 
using a Kaplan-Meier analysis, patients with 
MACs staining weakly or strongly for PAUF tend-
ed to have a shorter OS than those negative for 
PAUF (Figure 2, P = 0.1885). We conducted a 
statistical analysis to identify predictive factors 
for survival of ovarian MAC patients using a Cox 
regression assay (Table 4). In univariate analy-
sis, age at diagnosis (P = 0.002, hazard ratio 
[HR] = 1.097, 95% confidence interval [CI]: 
1.034-1.164), tumor stage (localized vs. dis-
tant, P = 0.016, HR = 7.099, 95% CI: 1.431-
35.206), and invasion pattern (expansile vs. 
infiltrative, P = 0.091, HR = 3.117, 95% CI: 
0.835-11.636) affected the OS of MAC 
patients. Age at diagnosis (P = 0.001, HR = 
1.090, 95% CI: 1.038-1.146), tumor stage 
(localized vs. distant, P = 0.006, HR = 9.175, 
95% CI: 1.899-44.334), and invasion pattern 
(expansile vs. infiltrative, P = 0.088, HR = 
2.724, 95% CI: 0.863-8.599) also affected the 
DFS of MAC patients. There was a tendency 
towards a shorter DFS in patients with MACs 
that stained strongly for PAUF than that in those 
with PAUF-negative MACs (P = 0.197, HR = 
4.134, 95% CI: 0.480-35.618). When we 
adjusted various parameters by multivariate 
analysis, older age at diagnosis and a distant 
tumor stage were associated with a shorter OS 
and DFS amongst MAC patients (Table 5). In 
particular, PAUF expression in MACs was an 
independent predictive factor for DFS (negative 
vs. weakly positive PAUF staining, P = 0.045, 
HR = 57.406, 95% CI: 1.090-3022.596 and 
negative vs. strongly positive PAUF staining, P = 
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0.034, HR = 97.890, 95% CI: 1.412-6785.95), 
although there was no statistical difference in 
DFS according to PAUF expression status using 
Kaplan-Meier survival analysis.
Discussion
PAUF, a novel tumor-specific protein, is known 
to be associated with cancer progression and 
metastasis in pancreatic ductal adenocarcino-
ma and ovarian tumors [11, 12]. MBTs are the 
most common type of borderline ovarian tumor 
and generally have an excellent prognosis. In 
contrast, MACs, although far less common, 
show an aggressive behavior [4-10]. We there-
fore hypothesized that PAUF expression status 
might be different between MBTs and MACs. 
As expected, we found that MACs were more 
frequently positive for PAUF expression than 
other ovarian mucinous tumors, with an 
increasing frequency of strong PAUF staining in 
MCA, MBT, and MAC tumor types. This sug-
gests that PAUF could be a sensitive and spe-
cific biomarker for distinguishing between inter-
mediate and malignant mucinous tumors of the 
ovary.
We also failed to find any significant differences 
in PAUF expression status of MBTs with respect 
to a range of clinicopathological features, which 
might reflect the generally low PAUF expression 
in these tumors. However, for MACs, PAUF 
expression tended to be higher in patients with 
a shorter OS. When we adjusted for possible 
confounders using multivariate Cox regression 
analysis, weak or strong PAUF expression in 
MAC was associated with a shorter DFS.
Our findings indicate that PAUF expression can 
help categorize ovarian mucinous tumors, and 
predicts shorter OS and DFS amongst MAC 
patients. Thus, PAUF could act as a prognostic 
and diagnostic biomarker for patients with an 
ovarian mucinous tumor.
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